Source disclosure: March 02, 2026, 10:00 JST
Kringle Pharma,Inc. [4884.T]
TOKYO, Mar 02 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported the monthly exercise status of its 16th warrant issue (exercise price adjustment clause attached) allocated to EVO FUND for February 2026.
In February, 416 warrants were exercised daily, totaling 416 warrants exercised throughout the month. As of the end of January 31, 2026, there were 1,244,000 shares outstanding, including treasury shares.
The total number of warrants issued was 17,000 units, representing a 100% issuance ratio based on the total number of warrants. At the end of February, 416 warrants remained unexercised, equivalent to 1,244,000 shares.
The exercise limit situation based on Article 434 of the listing regulations showed that the cumulative delivered share count was against the total listed shares, resulting in an exercise rate of 6,837,200%.
AI-translated content. 🟢 Confidence: High See terms • Original filing